Search
for
Sort by
Research 601–630 of 1000+
- HSD3B1 Genotypes Conferring Adrenal-Restrictive and Adrenal-Permissive Phenotypes in Prostate Cancer and Beyond
- The Association of Alopecia Areata-Related Emotional Symptoms with Work Productivity and Daily Activity Among Patients with Alopecia Areata
- Rare and common genetic determinants of metabolic individuality and their effects on human health
- Resident human dermal γδT-cells operate as stress-sentinels: Lessons from the hair follicle
- Risk Factors and Characterization of Vitiligo and Alopecia Areata in Patients With Chronic Graft-vs-Host Disease
- Photobiomodulation for the management of hair loss
- Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy
- Ejaculatory dysfunction in the treatment of lower urinary tract symptoms
- Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis
- Gender Differences in Response to COVID-19 Infection and Vaccination
- Alopecia in patients with COVID-19: A systematic review and meta-analysis
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- Analysis of dermatology-related search engine trends during the COVID-19 pandemic: Implications for patient demand for outpatient services and telehealth
- Impaired Hair Growth and Wound Healing in Mice Lacking Thyroid Hormone Receptors
- Bendamustine in Indolent Non-Hodgkin's Lymphoma: A Practice Guide for Patient Management
- Patient’s experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis
- Estimated serum vitamin D status, vitamin D intake, and risk of incident alopecia areata among US women
- Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities
- Anticancer effects of metformin on neuroendocrine tumor cells in vitro
- Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours
- Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience
- Sebaceous immunobiology - skin homeostasis, pathophysiology, coordination of innate immunity and inflammatory response and disease associations
- New developments in the molecular treatment of ichthyosis: review of the literature
- Alopecia Areata: An Update on Treatment Options for Children
- Cutaneous Lesions in the Rat Following Administration of an Irreversible Inhibitor of erbB Receptors, Including the Epidermal Growth Factor Receptor
- British Association of Dermatologists living guideline for managing people with alopecia areata 2024
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- The associated burden of mental health conditions in alopecia areata: a population‐based study in UK primary care*
- Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
- International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women